

Curriculum Vitae

Personal information **Esther Broekman**

Work experience

1. Employer: University Medical Centre Groningen
 - Start date: 102017
 - End date:
 - Position: Medical Oncologist
 - Activities:
 - Country: Netherlands
2. Employer: Medicines Evaluation Board
 - Start date: 112017
 - End date:
 - Position: Clinical Assessor oncology
 - Activities:
 - Country: Netherlands

Education and training

1. Subject: University Medical Center Groningen
 - Start date: 032022
 - End date:
 - Qualification: Clinical Pharmacology training
 - Organisation:
 - Country: Netherlands
2. Subject: University Medical Centre Groningen
 - Start date: 2014
 - End date: 102017
 - Qualification: Fellowship Medical Oncology
 - Organisation:
 - Country: Netherlands
3. Subject: Martini Hospital Groningen / University Medical Centre Groningen
 - Start date: 2010
 - End date: 102017
 - Qualification: Residency Internal Medicine
 - Organisation:
 - Country: Netherlands
4. Subject: Rijksuniversiteit Groningen
 - Start date: 2003
 - End date: 2010
 - Qualification: Bachelor and Master Medical Sciences (cum laude)
 - Organisation:
 - Country: Netherlands

Additional information

Publications

EC Jager, KE Broekman, S Kruijff, TP Links. State of the art and future directions in the systemic treatment of medullary thyroid cancer. *Curr Opin Oncol* 2022;34:1_8. R K Ismail, J van Breeschoten, M W J M Wouters, M van Dartel, S van der Flier, A K L Reyners, P de Graeff, A M G Pasmooij, A de Boer, K E Broekman, D L Hilarius. Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancer. *Breast* 2021;60:263_271. Broekman KE, van Kruchten, Sessa C, Jalving M and Reyners AKL. Clinical benefit of systemic therapies for recurrent ovarian cancer – ESMO_MCBS scores. *ESMO Open* 2021; 6: 100229. Broekman KE, Hof MAJ, Touw DJ, Gietema JA, Nijman HW, Lefrandt JD, Reyners AKL, Jalving M. Phase I study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced epithelial ovarian cancer. *Invest New Drugs* 2020; 38: 1454_1462. Aydemirli MD, Kapiteijn E, Ferrier KRM, Ottevanger N, Links TP, van der Horst-Schrivers ANA, Broekman KE, Groenwold RHH, Zwaveling J. Effectiveness and toxicity of lenvatinib in refractory thyroid cancer: Dutch real-life data. *Eur J Endocrinol* 2020; 182: 131_138. Broekman KE, Jalving M, van Tinteren H, Sessa C, Reyners AKL. Clinical benefit of controversial first line systemic therapies for advanced stage ovarian cancer – ESMO_MCBS scores. *Cancer Treat Rev* 2018; 69: 233_242. Reyners AK, Broekman KE, Glaudemans AW, Brouwers AH, Arts HJ, van der Zee AG, de Vries EG, Jalving M. Molecular imaging in ovarian cancer. *Ann Oncol* 2016; 27 suppl 1: i23_i29. Broekman KE, Sinkeler SJ, Waanders F, Bartels GL, Navis G, Janssen WM. Volume control in treatment-resistant congestive heart failure: role for peritoneal dialysis. *Heart Fail Rev* 2014; 19: 709_716.

Projects

Memberships

ASCO member ESMO member Dutch Thyroid Cancer Group Dutch Pharmacology Oncology Group 2017 Methods in Clinical Cancer Research (MCCR) workshop participant

Other Relevant Information